Recognizing the week of May 5 through 11, 2025, as "Lung Cancer Action Week" in Pennsylvania.
Summary
Senate Resolution 102 recognizes the week of May 5 through 11, 2025, as "Lung Cancer Action Week" in Pennsylvania. The resolution is largely commemorative and educational: it highlights lung cancer as the leading cause of cancer deaths in Pennsylvania and the United States, cites estimated 2025 diagnosis and mortality figures for the Commonwealth, and emphasizes the importance of screening, early detection, research funding, and public awareness.
The resolution also encourages residents to learn more about the detection and treatment of lung cancer and references the work of the American Lung Association’s LUNG FORCE initiative. It does not create a regulatory program, mandate coverage, or appropriate funds; instead, it uses the Senate’s formal recognition to promote advocacy and awareness around lung cancer prevention and treatment.
Impact
SR102 does not amend Pennsylvania statutes or alter agency authority. Its legal effect is limited to a formal Senate recognition of a designated awareness week and a public encouragement to seek information about lung cancer detection and treatment. The practical impact is symbolic and educational, aimed at patients, families, healthcare advocates, researchers, and public health organizations rather than changing rights, obligations, or benefits under state law.
Sentiment
The available context suggests broad, supportive sentiment. The resolution is sponsored by a bipartisan group of senators and contains no recorded opposition, committee debate, or vote history indicating controversy. Its findings frame lung cancer as a serious public health issue and present awareness, screening, and research as widely shared goals, which is consistent with a consensus-oriented commemorative resolution.
Contention
No specific points of contention appear in the provided materials. Because SR102 is a nonbinding awareness resolution, there is no evidence of disagreement over statutory changes, funding, or enforcement. Any potential policy differences would likely relate generally to priorities for cancer research funding, screening access, or public health messaging, but none are raised in the text or legislative history provided.